Palvella Therapeutics Inc (PVLA) Stock Price, Quote & News

Company Profile

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN 3.9% rapamycin anhydrous gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR...

Industry: Biotechnology

Sector: Healthcare

Phone: 484 253 1461

Website: palvellatx.com

Address:

125 Strafford Avenue, Suite 360, Wayne, United States

Mahvalousday Feb. 24 at 12:05 AM

$PVLA these type stocks don’t generally hold a conference call to announce bad news. Just a matter how good it was is the question but the fact the results are early is a good sign

1 · Reply

Eagley3k Feb. 23 at 11:17 PM

$PVLA why not lay out the PR now???

1 · Reply

DekmarTrades Feb. 23 at 10:18 PM

$PVLA Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

1 · Reply

TinyTiger19 Feb. 23 at 5:37 PM

”@SqueezeSharkie moving different. Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $THM $VEEE $IMRN $PVLA •

0 · Reply

_EmproX Feb. 23 at 4:19 PM

$PVLA $BOF $DLXY $FSM ~•~

0 · Reply

TinyTiger19 Feb. 23 at 4:18 PM

$BCAB $STTK $LRE $PVLA •’”

0 · Reply

TheLearningTrader Feb. 19 at 8:17 PM

$PVLA long here for data Phase 2 had stellar results and phase 3 is similar study with more patients should hit Target 120

0 · Reply

OfficialStocktwitsUser Feb. 16 at 7:23 PM

$PVLA RSI: 44.09, MACD: -3.8302 Vol: 6.81, MA20: 83.97, MA50: 92.79 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

UgoGreg Feb. 15 at 9:55 PM

$PVLA https://youtu.be/ygBN8MilTyc

0 · Reply

StarryReturns Feb. 4 at 3:15 PM

$PVLA is a specialty pharmaceutical company with a focus on hospital-based drugs; it operates in a niche with moderate growth but faces pricing pressure.

0 · Reply

Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis

Jan 22, 2026, 10:26 AM EST - 4 weeks ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Jan 9, 2026, 7:30 AM EST - 6 weeks ago

Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies

Jan 7, 2026, 7:30 AM EST - 6 weeks ago

Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

Dec 23, 2025, 10:43 AM EST - 2 months ago

Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst

Dec 16, 2025, 7:30 AM EST - 2 months ago

Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas

Dec 15, 2025, 6:00 AM EST - 2 months ago

Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies

Nov 11, 2025, 7:30 AM EST - 3 months ago

Palvella Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 7:30 AM EST - 3 months ago

Palvella Therapeutics to Present at the Stifel 2025 Healthcare Conference

Nov 5, 2025, 6:00 AM EST - 3 months ago

Palvella Therapeutics Announces New QTORIN™ Product Candidate, QTORIN™ Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis (DSAP), a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies

Nov 4, 2025, 7:30 AM EST - 3 months ago

Palvella Therapeutics to Host Third Quarter 2025 Financial Results and Corporate Update Conference Call on November 11, 2025

Oct 13, 2025, 7:30 AM EDT - 4 months ago

U.S. Food and Drug Administration Awards Year Two Proceeds from Orphan Products Grant Supporting Palvella Therapeutics' Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

Sep 24, 2025, 6:00 AM EDT - 5 months ago

Palvella Therapeutics Announces Expansion of QTORIN™ Rapamycin's Development into Clinically Significant Angiokeratomas, a Rare, Chronically Debilitating Lymphatic Disease with No FDA-approved Therapies

Sep 22, 2025, 7:30 AM EDT - 5 months ago

Palvella Therapeutics: QTORIN Nears Phase 3 Readout For MLM

Sep 17, 2025, 7:30 AM EDT - 5 months ago

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Sep 15, 2025, 7:30 AM EDT - 5 months ago

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Sep 3, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Aug 28, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Aug 14, 2025, 7:30 AM EDT - 6 months ago

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Aug 5, 2025, 7:30 AM EDT - 7 months ago

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Jun 30, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Jun 23, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Jun 18, 2025, 7:30 AM EDT - 8 months ago

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

Jun 9, 2025, 7:30 AM EDT - 9 months ago

Palvella Therapeutics Receives Initial Proceeds from FDA Orphan Products Grant to Support Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations

May 27, 2025, 8:00 AM EDT - 9 months ago

Palvella Therapeutics Strengthens Executive Leadership Team with Appointment of Rare Disease Commercial Veteran Ashley Kline as Chief Commercial Officer

May 15, 2025, 7:30 AM EDT - 10 months ago

Palvella Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 7:30 AM EDT - 10 months ago

Palvella Therapeutics to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

May 5, 2025, 7:30 AM EDT - 10 months ago

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

Apr 23, 2025, 4:15 PM EDT - 10 months ago

Palvella Therapeutics Announces Abstract Highlighting the Estimated Diagnosed Prevalence and Annual Incidence of Lymphatic Malformations in the U.S. Accepted for Poster Presentation at the 82nd Annual Meeting of the Society for Investigative Dermatology

Apr 22, 2025, 7:30 AM EDT - 10 months ago

Palvella Therapeutics Granted Additional U.S. Patent for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Apr 11, 2025, 7:30 AM EDT - 11 months ago

Palvella Therapeutics Announces QTORIN™ Rapamycin 3.9% Anhydrous Gel for the Treatment of Microcystic Lymphatic Malformations Featured in Oral Presentation by Amy Paller, M.S., M.D., Chair of Dermatology at Northwestern University's Feinberg School of Medicine, at the 15th World Congress of Pediatric Dermatology

Apr 2, 2025, 8:00 AM EDT - 11 months ago

Palvella Therapeutics Announces Late-Breaking Oral Presentation at the 15th World Congress of Pediatric Dermatology

Mar 31, 2025, 7:30 AM EDT - 11 months ago

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Palvella Therapeutics to Host Full Year 2024 Financial Results Conference Call on March 31, 2025

Feb 25, 2025, 8:00 AM EST - 1 year ago

Palvella Therapeutics to Present at the TD Cowen 45th Annual Healthcare Conference

Feb 10, 2025, 8:00 AM EST - 1 year ago

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old

Dec 13, 2024, 2:55 PM EST - 1 year ago

Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million

Mahvalousday Feb. 24 at 12:05 AM

$PVLA these type stocks don’t generally hold a conference call to announce bad news. Just a matter how good it was is the question but the fact the results are early is a good sign

1 · Reply

Eagley3k Feb. 23 at 11:17 PM

$PVLA why not lay out the PR now???

1 · Reply

DekmarTrades Feb. 23 at 10:18 PM

1 · Reply

TinyTiger19 Feb. 23 at 5:37 PM

”@SqueezeSharkie moving different. Ice-cold vision, pure substance. Costs you nothing but a tap, follow him now!! $THM $VEEE $IMRN $PVLA •

0 · Reply

_EmproX Feb. 23 at 4:19 PM

$PVLA $BOF $DLXY $FSM ~•~

0 · Reply

TinyTiger19 Feb. 23 at 4:18 PM

$BCAB $STTK $LRE $PVLA •’”

0 · Reply

TheLearningTrader Feb. 19 at 8:17 PM

$PVLA long here for data Phase 2 had stellar results and phase 3 is similar study with more patients should hit Target 120

0 · Reply

OfficialStocktwitsUser Feb. 16 at 7:23 PM

0 · Reply

UgoGreg Feb. 15 at 9:55 PM

$PVLA https://youtu.be/ygBN8MilTyc

0 · Reply

StarryReturns Feb. 4 at 3:15 PM

$PVLA is a specialty pharmaceutical company with a focus on hospital-based drugs; it operates in a niche with moderate growth but faces pricing pressure.

0 · Reply

prismmarketview Feb. 2 at 8:59 PM

Palvella Therapeutics (NASDAQ: $PVLA) edged about 5% higher after a new systematic review in Clinical and Experimental Dermatology reinforced the mechanistic and clinical rationale for topical statins in porokeratosis, bolstering support for its QTORIN pitavastatin program alongside the ongoing Phase 3 QTORIN rapamycin effort in microcystic lymphatic malformations. https://prismmarketview.com/palvella-therapeutics-shares-rise-5-after-scientific-publication-highlights-unmet-need-in-rare-skin-disease/

0 · Reply

BioTuesdays Feb. 2 at 6:14 PM

$PVLA announced that Clinical and Experimental Dermatology has published a peer-reviewed systematic review synthesizing clinical evidence on off-label topical statin use in porokeratosis, supporting the scientific rationale and clinical potential of its QTORIN pitavastatin for treating disseminated superficial actinic porokeratosis (DSAP) https://biotuesdays.com/2026/02/02/publication-supports-scientific-rationale-for-palvellas-qtorin-in-dsap/

0 · Reply

Quantumup Feb. 2 at 12:49 PM

TD Cowen⬆️ $PVLA's PT to $190 from $133 and reiterated at a Buy rating. $NVS $PFE $TEVA TD Cowen said in its note: PVLA held a successful BTD advice meeting for QTORIN rapa in cVM v. recently and intends to file for BTD shortly. The meeting was attended by sr. FDA division leadership who heard strongly supportive KOL opinion of QTORIN rapa's efficacy in cVM. We have high conviction QTORIN rapa will receive BTD in cVM, which could allow FDA alignment on a single-arm Ph3 design, expediting data and approval.

0 · Reply

Eagley3k Jan. 30 at 8:21 PM

$PVLA found a support around $73. heavy volume accumulation. Time for reversal?

0 · Reply

Jcljack26 Jan. 30 at 5:32 PM

$PVLA $40 off the high and half of most price targets.

0 · Reply

OfficialStocktwitsUser Jan. 27 at 9:46 PM

$PVLA RSI: 44.31, MACD: -2.0767 Vol: 6.75, MA20: 96.45, MA50: 95.87 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

dianahilla Jan. 25 at 1:35 PM

$PVLA what happened?

0 · Reply

Eagley3k Jan. 25 at 1:11 PM

$PVLA $TARA is there a chance if the government shuts down, data could be delayed?? Appreciate well informed investors' opinion

1 · Reply

Eagley3k Jan. 23 at 9:48 PM

$PVLA got in today. seems like H&S but I'm hoping it will fail.

0 · Reply

SuperGreenToday Jan. 21 at 6:26 AM

$PVLA Share Price: $97.67 Contract Selected: Aug 21, 2026 $100 Calls Buy Zone: $28.69 – $35.44 Target Zone: $53.60 – $65.51 Potential Upside: 76% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

judgeyoung2 Jan. 14 at 4:24 PM

$PVLA march

0 · Reply

1986iamwallstreet Jan. 12 at 2:53 PM

$PVLA will get bought out

0 · Reply

Market Cap	1.01B
Revenue (ttm)	0.00
Net Income (ttm)	-17.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	334,200
Avg Vol	282,318
Day's Range	N/A - N/A
Shares Out	11.84M
Stochastic %K	69%
Beta	-0.16
Analysts	Strong Sell
Price Target	$190.50